What's happening With Veru?
Veru (VERU) stock rose on Wednesday after announcing that the Phase 2 results evaluating enobosarm in patients with breast cancer showed positive clinical benefits. Shares of the company were trading higher 1.84% to $8.86 a share on Wednesday.
Enobosarm is an oral, first-in-class, new chemical entity, selective androgen receptor targeting agonist that activates the androgen receptor, tumor suppressor, in metastatic breast cancer.
“Despite progressing on the standard of care, patients treated with enobosarm had significant clinical responses”, said Professor Carlo Palmieri, BSc, MB BS, PhD, FRCP, Professor of Translational Oncology & Medical Oncologist, University of Liverpool and the presenter of the results at the Congress. Adding, “Targeting the androgen receptor, a tumor suppressor in breast cancer, provides us with a potential novel endocrine therapy with an excellent safety profile.”
What Does This Mean For Veru?
All the data from the Phase 2 trial will be presented at the European Society for Medical Oncology Breast Cancer Virtual Congress 2021. The biotech company is scheduled to release its 2021 second-quarter financial results on May 12th, 2021.
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners.
VERU has an Overall Score of 54. Find out what this means to you and get the rest of the rankings on VERU!
Veru Inc is a biopharmaceutical company focused on urology and oncology. It develops prescription products for benign prostatic hyperplasia hot flashes associated with cancer treatment, male infertility, and novel chemotherapies for a variety of cancers. The company currently operates in two reporting segments: Sexual health business and Research & development. Some of its products include Zuclomiphene, Veru-111, Veru-100, FC2, and Roman Swipes. The company generates the majority of its revenue from the United States.
